Loading clinical trials...

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

MK0476 Phase III Double-Blind Comparative Study - Allergic Rhinitis

NCT00127647•Organon and Co

Summary

The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis.

Eligibility

Age

15 - 64 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Japanese males and females with a 2-year documented history of seasonal allergic rhinitis symptoms and positive allergy testing (cedar, alder and/or cypress)

Exclusion Criteria

•Patients with drug-induced rhinitis or non-allergic rhinitis, or patients who used anti-histamine drugs (within 2 weeks) before the start of the observation period

Key Dates

Start Date

November 1, 2004

Primary Completion Date

April 1, 2005

Completion Date

April 1, 2005

Last Updated

August 15, 2024

Enrollment

1,375

ACTUAL participants

Conditions

Rhinitis, Allergic, Seasonal

Interventions

montelukast sodium

DRUG

Comparator: pranlukast

DRUG

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

NCT00406783

Rhinitis, Allergic, SeasonalRhinitis, Allergic, Perennial

View study

COMPLETEDPHASE3

Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever

NCT00135629

Rhinitis, Allergic, Seasonal

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 15, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

Inclusion Criteria

Exclusion Criteria

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever

Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.

Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)